Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble

MT Newswires Live06-08

Arcturus Therapeutics (ARCT) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis.

Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled therapeutic generally was safe and well tolerated among the healthy patients participating in the early-stage trial as well as the four adult patients with cystic fibrosis.

Lung function also improved in the cystic fibrosis patients after they received two doses of ARCT-032, the company said. It plans to complete phase 1b shortly.

Price: 30.10, Change: -12.50, Percent Change: -29.34

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441509090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-08 03:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2441509090","market":"sh","top_or_hot":-1,"title":"Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble","media":"MT Newswires Live","content":"<html><body><p> Arcturus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ARCT) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis.</p><p>Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled therapeutic generally was safe and well tolerated among the healthy patients participating in the early-stage trial as well as the four adult patients with cystic fibrosis.</p><p>Lung function also improved in the cystic fibrosis patients after they received two doses of ARCT-032, the company said. It plans to complete phase 1b shortly.</p><p>Price: 30.10, Change: -12.50, Percent Change: -29.34</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-08 03:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcturus Therapeutics (ARCT) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2441509090","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441509090","pubTimestamp":1717787774,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arcturus Therapeutics  slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis.Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled therapeutic generally was safe and well tolerated among the healthy patients participating in the early-stage trial as well as the four adult patients with cystic fibrosis.Lung function also improved in the cystic fibrosis patients after they received two doses of ARCT-032, the company said. It plans to complete phase 1b shortly.Price: 30.10, Change: -12.50, Percent Change: -29.34","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","ARCT":"Arcturus Therapeutics Ltd.","BK4139":"生物科技"},"translate_title":"Arcturus Therapeutics前瞻性囊性纤维化治疗显示出积极结果——股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ARCT":0.9},"content_text":"Arcturus Therapeutics (ARCT) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis.Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled therapeutic generally was safe and well tolerated among the healthy patients participating in the early-stage trial as well as the four adult patients with cystic fibrosis.Lung function also improved in the cystic fibrosis patients after they received two doses of ARCT-032, the company said. It plans to complete phase 1b shortly.Price: 30.10, Change: -12.50, Percent Change: -29.34","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441509090"}